Cargando…
Transgenic Knockdown of Cardiac Sodium/Glucose Cotransporter 1 (SGLT1) Attenuates PRKAG2 Cardiomyopathy, Whereas Transgenic Overexpression of Cardiac SGLT1 Causes Pathologic Hypertrophy and Dysfunction in Mice
BACKGROUND: The expression of a novel cardiac glucose transporter, SGLT1, is increased in glycogen storage cardiomyopathy secondary to mutations in PRKAG2. We sought to determine the role of SGLT1 in the pathogenesis of PRKAG2 cardiomyopathy and its role in cardiac structure and function. METHODS AN...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310371/ https://www.ncbi.nlm.nih.gov/pubmed/25092788 http://dx.doi.org/10.1161/JAHA.114.000899 |
_version_ | 1782354860424822784 |
---|---|
author | Ramratnam, Mohun Sharma, Ravi K. D'Auria, Stephen Lee, So Jung Wang, David Huang, Xue Yin N. Ahmad, Ferhaan |
author_facet | Ramratnam, Mohun Sharma, Ravi K. D'Auria, Stephen Lee, So Jung Wang, David Huang, Xue Yin N. Ahmad, Ferhaan |
author_sort | Ramratnam, Mohun |
collection | PubMed |
description | BACKGROUND: The expression of a novel cardiac glucose transporter, SGLT1, is increased in glycogen storage cardiomyopathy secondary to mutations in PRKAG2. We sought to determine the role of SGLT1 in the pathogenesis of PRKAG2 cardiomyopathy and its role in cardiac structure and function. METHODS AND RESULTS: Transgenic mice with cardiomyocyte‐specific overexpression of human T400N mutant PRKAG2 cDNA (TG(T400N)) and transgenic mice with cardiomyocyte‐specific RNA interference knockdown of SGLT1 (TG(SGLT1‐DOWN)) were crossed to produce double‐transgenic mice (TG(T400N)/TG(SGLT1‐DOWN)). Tet‐off transgenic mice conditionally overexpressing cardiac SGLT1 in the absence of doxycycline were also constructed (TG(SGLT‐ON)). Relative to TG(T400N) mice, TG(T400N)/TG(SGLT1‐DOWN) mice exhibited decreases in cardiac SGLT1 expression (63% decrease, P<0.05), heart/body weight ratio, markers of cardiac hypertrophy, and cardiac glycogen content. TG(T400N)/TG(SGLT1‐DOWN) mice had less left ventricular dilation at age 12 weeks compared to TG(T400N) mice. Relative to wildtype (WT) mice, TG(SGLT1‐ON) mice exhibited increases in heart/body weight ratio, glycogen content, and markers of cardiac hypertrophy at ages 10 and 20 weeks. TG(SGLT1‐ON) mice had increased myocyte size and interstitial fibrosis, and progressive left ventricular dysfunction. When SGLT1 was suppressed after 10 weeks of overexpression (TG(SGLT1‐ON/OFF)), there was a reduction in cardiac hypertrophy and improvement in left ventricular failure. CONCLUSIONS: Cardiac knockdown of SGLT1 in a murine model of PRKAG2 cardiomyopathy attenuates the disease phenotype, implicating SGLT1 in the pathogenesis. Overexpression of SGLT1 causes pathologic cardiac hypertrophy and left ventricular failure that is reversible. This is the first report of cardiomyocyte‐specific transgenic knockdown of a target gene. |
format | Online Article Text |
id | pubmed-4310371 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-43103712015-02-10 Transgenic Knockdown of Cardiac Sodium/Glucose Cotransporter 1 (SGLT1) Attenuates PRKAG2 Cardiomyopathy, Whereas Transgenic Overexpression of Cardiac SGLT1 Causes Pathologic Hypertrophy and Dysfunction in Mice Ramratnam, Mohun Sharma, Ravi K. D'Auria, Stephen Lee, So Jung Wang, David Huang, Xue Yin N. Ahmad, Ferhaan J Am Heart Assoc Original Research BACKGROUND: The expression of a novel cardiac glucose transporter, SGLT1, is increased in glycogen storage cardiomyopathy secondary to mutations in PRKAG2. We sought to determine the role of SGLT1 in the pathogenesis of PRKAG2 cardiomyopathy and its role in cardiac structure and function. METHODS AND RESULTS: Transgenic mice with cardiomyocyte‐specific overexpression of human T400N mutant PRKAG2 cDNA (TG(T400N)) and transgenic mice with cardiomyocyte‐specific RNA interference knockdown of SGLT1 (TG(SGLT1‐DOWN)) were crossed to produce double‐transgenic mice (TG(T400N)/TG(SGLT1‐DOWN)). Tet‐off transgenic mice conditionally overexpressing cardiac SGLT1 in the absence of doxycycline were also constructed (TG(SGLT‐ON)). Relative to TG(T400N) mice, TG(T400N)/TG(SGLT1‐DOWN) mice exhibited decreases in cardiac SGLT1 expression (63% decrease, P<0.05), heart/body weight ratio, markers of cardiac hypertrophy, and cardiac glycogen content. TG(T400N)/TG(SGLT1‐DOWN) mice had less left ventricular dilation at age 12 weeks compared to TG(T400N) mice. Relative to wildtype (WT) mice, TG(SGLT1‐ON) mice exhibited increases in heart/body weight ratio, glycogen content, and markers of cardiac hypertrophy at ages 10 and 20 weeks. TG(SGLT1‐ON) mice had increased myocyte size and interstitial fibrosis, and progressive left ventricular dysfunction. When SGLT1 was suppressed after 10 weeks of overexpression (TG(SGLT1‐ON/OFF)), there was a reduction in cardiac hypertrophy and improvement in left ventricular failure. CONCLUSIONS: Cardiac knockdown of SGLT1 in a murine model of PRKAG2 cardiomyopathy attenuates the disease phenotype, implicating SGLT1 in the pathogenesis. Overexpression of SGLT1 causes pathologic cardiac hypertrophy and left ventricular failure that is reversible. This is the first report of cardiomyocyte‐specific transgenic knockdown of a target gene. Blackwell Publishing Ltd 2014-08-01 /pmc/articles/PMC4310371/ /pubmed/25092788 http://dx.doi.org/10.1161/JAHA.114.000899 Text en © 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/3.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Research Ramratnam, Mohun Sharma, Ravi K. D'Auria, Stephen Lee, So Jung Wang, David Huang, Xue Yin N. Ahmad, Ferhaan Transgenic Knockdown of Cardiac Sodium/Glucose Cotransporter 1 (SGLT1) Attenuates PRKAG2 Cardiomyopathy, Whereas Transgenic Overexpression of Cardiac SGLT1 Causes Pathologic Hypertrophy and Dysfunction in Mice |
title | Transgenic Knockdown of Cardiac Sodium/Glucose Cotransporter 1 (SGLT1) Attenuates PRKAG2 Cardiomyopathy, Whereas Transgenic Overexpression of Cardiac SGLT1 Causes Pathologic Hypertrophy and Dysfunction in Mice |
title_full | Transgenic Knockdown of Cardiac Sodium/Glucose Cotransporter 1 (SGLT1) Attenuates PRKAG2 Cardiomyopathy, Whereas Transgenic Overexpression of Cardiac SGLT1 Causes Pathologic Hypertrophy and Dysfunction in Mice |
title_fullStr | Transgenic Knockdown of Cardiac Sodium/Glucose Cotransporter 1 (SGLT1) Attenuates PRKAG2 Cardiomyopathy, Whereas Transgenic Overexpression of Cardiac SGLT1 Causes Pathologic Hypertrophy and Dysfunction in Mice |
title_full_unstemmed | Transgenic Knockdown of Cardiac Sodium/Glucose Cotransporter 1 (SGLT1) Attenuates PRKAG2 Cardiomyopathy, Whereas Transgenic Overexpression of Cardiac SGLT1 Causes Pathologic Hypertrophy and Dysfunction in Mice |
title_short | Transgenic Knockdown of Cardiac Sodium/Glucose Cotransporter 1 (SGLT1) Attenuates PRKAG2 Cardiomyopathy, Whereas Transgenic Overexpression of Cardiac SGLT1 Causes Pathologic Hypertrophy and Dysfunction in Mice |
title_sort | transgenic knockdown of cardiac sodium/glucose cotransporter 1 (sglt1) attenuates prkag2 cardiomyopathy, whereas transgenic overexpression of cardiac sglt1 causes pathologic hypertrophy and dysfunction in mice |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310371/ https://www.ncbi.nlm.nih.gov/pubmed/25092788 http://dx.doi.org/10.1161/JAHA.114.000899 |
work_keys_str_mv | AT ramratnammohun transgenicknockdownofcardiacsodiumglucosecotransporter1sglt1attenuatesprkag2cardiomyopathywhereastransgenicoverexpressionofcardiacsglt1causespathologichypertrophyanddysfunctioninmice AT sharmaravik transgenicknockdownofcardiacsodiumglucosecotransporter1sglt1attenuatesprkag2cardiomyopathywhereastransgenicoverexpressionofcardiacsglt1causespathologichypertrophyanddysfunctioninmice AT dauriastephen transgenicknockdownofcardiacsodiumglucosecotransporter1sglt1attenuatesprkag2cardiomyopathywhereastransgenicoverexpressionofcardiacsglt1causespathologichypertrophyanddysfunctioninmice AT leesojung transgenicknockdownofcardiacsodiumglucosecotransporter1sglt1attenuatesprkag2cardiomyopathywhereastransgenicoverexpressionofcardiacsglt1causespathologichypertrophyanddysfunctioninmice AT wangdavid transgenicknockdownofcardiacsodiumglucosecotransporter1sglt1attenuatesprkag2cardiomyopathywhereastransgenicoverexpressionofcardiacsglt1causespathologichypertrophyanddysfunctioninmice AT huangxueyinn transgenicknockdownofcardiacsodiumglucosecotransporter1sglt1attenuatesprkag2cardiomyopathywhereastransgenicoverexpressionofcardiacsglt1causespathologichypertrophyanddysfunctioninmice AT ahmadferhaan transgenicknockdownofcardiacsodiumglucosecotransporter1sglt1attenuatesprkag2cardiomyopathywhereastransgenicoverexpressionofcardiacsglt1causespathologichypertrophyanddysfunctioninmice |